Viewing all links from the source for category: Pharma/Biotech

21/03/2025

These ASX companies are stepping up to tackle traumatic brain injury head-on

AdAlta: First external investment secured for “East to West” cellular immunotherapy strategy

20/03/2025

Imugene: Azer-cel granted FDA Fast Track Designation in blood cancer DLBCL

17/03/2025

OGTR: Clinical trial of GM vaccinia virus for the treatment of solid tumours

13/03/2025

Noxopharm: Doherty Clinical Trials to host HERACLES trial

11/03/2025

MJA: Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross‐sectional analysis

Study raises concern about opioid prescribing to injured Australian workers – Monash University

07/03/2025

Novotech Releases Hepatitis B Global Clinical Trial Landscape Report 2025

06/03/2025

AdAlta receives advance on its FY25 R&D Tax Incentive rebate

Clarity Pharmaceuticals: SECuRE trial update: 92% of pre-chemo participantsexperience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences

05/03/2025

Global Tech Giant Opens Headquarters In Victoria

04/03/2025

Lumos announces expanded scope of work under Hologic fFN development agreement

Radiopharm Theranostics: Interim Report:Half Year Ended 31 December 2024

National consensus statement on opioid agonist treatment in custodial settings

03/03/2025

Amplia: TYPE D MEETING OUTCOME WITH US FOOD AND DRUG ADMINISTRATION

28/02/2025

Neuren: 2024 results: A$166 million comprehensive income for shareholders

TruScreen Signs MOU with Hangzhou Dalton Bioscience to Expand its HPV Product Offerings

Neuren: DAYBUE™ (trofinetide) 2024 net sales US$348 million

Imugene granted India patent for oncolytic virotherapy CF33

27/02/2025

Imugene: OnCARlytics patent allowance in China

Starpharma: Interim Report and Half-Year Financial Results

Invion: EXPANDED COLLABORATION & FUNDING AGREEMENT WITH MAJOR SOUTH KOREAN PHARMACEUTICAL GROUP HANLIM TO INCLUDE OESOPHAGEAL CANCER

England subsidises drugs like Ozempic for weight loss. Could Australia follow?

Telix Pharma CEO in $120m block trade; taps JPMorgan

26/02/2025

Failure to overturn Cootamundra Pathology Lab Closure results in 24-hour strike – Health Services Union

MS patients suffer side-effects after NHS England switches to cheaper drug

Big pharma sues GenesisCare over Labor-endorsed copycat cancer drug

24/02/2025

Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability

Star biotech Telix makes $1.2b revenue pledge

20/02/2025

Wesfarmers half-year report

Sonic Healthcare: RESULTS FOR THE HALF YEAR ENDED 31 DECEMBER 2024

19/02/2025

Nyrada Half Year FY2025 Results

18/02/2025

Syntara: Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars

Neurizon: FDA Guidance on NUZ-001 IND Application

Recce Pharmaceuticals: Positive Phase II Data from Clinical Trial of RECCE® 327 GelSupports Accelerated Commercialisation Pathway

17/02/2025

Imugene: Azer-cel demonstrates two additional Complete Responses in CD19 CAR-T Phase 1b Trial with 57% Complete Response Rate

11/02/2025

INOVIQ establishes medical and scientific advisory board

31/01/2025

Inoviq: KEY MILESTONES ACHIEVED IN DIAGNOSTICS AND THERAPEUTICS

OPTISCAN RECEIVES $1.775m R&D TAX REFUND

Optiscan QUARTERLY ACTIVITIES & CASHFLOW REPORT

Little Green Pharma: Quarterly activities report

Radiopharm Theranostics: Quarterly Activities/Appendix 4C Cash Flow Report

Oncosil: Quarterly Activities and cash flow report

Amplia: QUARTERLY ACTIVITIES AND CASH FLOW REPORTS

LTR Pharma: December 2024 Quarterly Activities Report and Appendix 4C

Neurizon: Quarterly Report & Appendix 4C Q2 FY25

30/01/2025

Imugene receives A$20 million for convertible notes issue

Syntara: Quarterly Shareholder Report | December 2024

Starpharma: Quarterly Activities Report & Appendix 4C

Noxopharm: December 2024 Quarterly Activities Report and Appendix 4C